問卷

TPIDB > Search Result

Search Result

篩選

List

4Cases

2025-03-31 - 2028-06-30

Active
A retrospective, observational post-marketing study evaluating the efficacy and safety of intravenously administered polymyxin B and colistin methanesulfonate in treating patients with carbapenem-resistant, Gram-negative bacterial infections.
  • Condition/Disease

    1. Clinical response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC (End of Treatment (EOT) + 7 days). 2. Clinical response rate of the two treatment groups at TOC. 3. Microbiological response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC. 4. Microbiological response rate of the two treatment groups at TOC. 5. All-cause mortality rate of the two treatment groups at day 28. 6. Infection-related mortality rate of the two treatment groups at day 28.

  • Test Drug

    POLYMYXIN B SULFATE

Participate Sites
13Sites

Recruiting13Sites

2022-09-30 - 2026-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-12-23 - 2024-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-08-01 - 2022-07-31

Phase II

The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness(OSA)
  • Condition/Disease

    Obstructive Sleep Apnea of Adult, Mild Cognitive Impairment

  • Test Drug

    18F-AV-45 (AV-45/Amyvid): (E)-4-(2-(6-(2-(2-(2-[18F] fluoroethoxyl) ethoxy)ethoxy)pyridine-3-yl)vinyl)-N-methylbenzenamine,10

Participate Sites
4Sites

Recruiting4Sites